Abstract:Background: Chromatin regulators (CRs) serve as indispensable factors in tumor biological processes by influencing tumorigenesis and the immune microenvironment and have been identified in head and neck squamous cell carcinoma (HNSCC). Hence, CR-related genes (CRRGs) are considered potential biomarkers for predicting prognosis and immune infiltration in HNSCC. In this study, we established a novel signature for predicting the prognosis and immunotherapeutic response of HSNCC. background: CRs serve as indispensable factors in tumor biological processes by influencing tumorigenesis and the immune microenvironment and have been identified in HNSCC. Hence, CR-related genes (CRRGs) are considered potential biomarkers to predict prognosis and immune infiltration in HNSCC. Methods: A total of 870 CRRGs were obtained according to previous studies. Subsequently, patients in the TCGA-HNSC cohort were divided into different clusters based on the expression of prognostic CRRGs. Kaplan‒Meier (K‒M) survival analysis was conducted to compare the prognosis in clusters, and the CIBERSORT and ssGSEA methods assessed the immune infiltration status. In addition, the differences in immunotherapeutic responses were determined based on the TICA database. Furthermore, the differentially expressed CRRGs between clusters were identified, and the predictive signature was established according to the results of univariate Cox, least absolute shrinkage and selection operator regression analysis, and multivariate Cox. The predictive effects of the risk model were evaluated according to the area under the receiver operating characteristic (ROC) curve (AUC) in both the training and external test cohorts. A nomogram was established, and survival comparisons, functional enrichment analyses, and immune infiltration status and clinical treatment assessments were performed. In addition, the hub gene network and related analysis were conducted with the Cytohubba application. objective: Objective: In this study, we established a novel signature to predict the prognosis and immunotherapeutic response in HSNCC. Results: Based on the expression of prognostic CRRGs, patients were divided into two clusters, in which Cluster 1 exhibited a better prognosis, more enriched immune infiltration, and a better immunotherapeutic response but exhibited chemotherapy sensitivity. The AUC values of the 1-, 3- and 5- year ROC curves for the risk model were 0.673, 0.732, and 0.692, respectively, as well as 0.645, 0.608, and 0.623 for the test set. In addition, patients in the low-risk group exhibited more immune cell enrichment and immune function activation, as well as a better immunotherapy response. The hub gene network indicated ACTN2 as the core gene differentially expressed between the two risk groups. method: A total of 870 CRRGs were obtained according to previous studies. Subsequently, patients in the TCGA-HNSC cohort were divided into different clusters based on the expression of prognostic CRRGs. Kaplan‒Meier (K-M) survival analysis was conducted to compare the prognosis in clusters, and the immune infiltration status was assessed by the CIBERSORT and ssGSEA methods. In addition, the differences in immunotherapeutic response were determined by the TICA database. Furthermore, the differentially expressed CRRGs between clusters were identified, and the predictive signature was established according to the results of univariate Cox, least absolute shrinkage and selection operator regression analysis and multivariate Cox. The predictive effects of the risk model were evaluated by the area under the curve (AUC) of receiver operating characteristic curves (ROC) in both the training and external test cohorts. A nomogram was established, and the survival comparison, functional enrichment analysis, immune infiltration status and clinical treatment were assessed. In addition, the hub gene network and related analysis were conducted with the Cytohubba application. Conclusions: We identified molecular subtypes and established a novel predictive signature based on CRRGs. This effective CRRS system can possibly provide a novel research direction for exploring the correlation between CRs and HNSCC and requires further experimental validation. result: Based on the expression of prognostic CRRGs, patients were divided into two clusters, in which cluster 1 exhibited a better prognosis, more enriched immune infiltration, and a better immunotherapeutic response but exhibited chemotherapy sensitivity. The AUC values of the 1-, 3- and 5-year ROC curves for the risk model were 0.673, 0.732 and 0.692, respectively, as well as 0.645, 0.608 and 0.623 for the test set. In addition, patients in the low-risk groups exhibited more immune cell enrichment and immune function activation as well as a better immunotherapy response. The hub gene network indicated ACTN2 as the core gene expressed differentially between the two risk groups. conclusion: We identified molecular subtypes and established a novel predictive signature based on CRRGs. This effective CRRS system can predict HNSCC patients reliably and provide ideal suggestions to formulate individual treatment.

Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma

Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival

Serum CCL2 and Serum TNF-α – Two New Biomarkers Predict Bone Invasion, Post-Treatment Distant Metastasis and Poor Overall Survival in Nasopharyngeal Carcinoma

Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Serum Prognostic Markers in Head and Neck Cancer

Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era

The Prognostication of Surgically Resected Head and Neck Squamous Cell Carcinoma Using Pre‐Therapy Neutrophil and Lymphocyte Counts

Prediction of Clinical Outcome in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy by Plasma Markers

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma

Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer

Predictive Values Profiling of Interleukin-2, Interleukin-8, Tumor Necrosis Factor-Α, Procalcitonin, and C-reactive Protein in Critical Gastrointestinal Cancer Patients.

Serum C-Reactive Protein (CRP) As a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy

Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC

The Predictive Role of Inflammatory Biomarkers in Patients With Larynx Cancer Undergoing Definitive Radiotherapy

Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy

Natural killer cell‐based signature: Prognostic analysis in head and neck squamous cell carcinoma

Prognostic Implications of Plasma Fibrinogen and Serum C-Reactive Protein Levels in Non-Small Cell Lung Cancer Resection and Survival

Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia